JasonWestinMD

PubMed

• The future of immunotherapy for diffuse large B-cell lymphoma.
  Johannes Duell, Jason Westin
  International Journal of Cancer. 2025-01-15
• Early-Stage Extranodal NK/T-Cell Lymphoma, Nasal Type: A Role for Elective Nodal Irradiation?
  Penny Fang, Sonal S Noticewala, Susan Y Wu, Jillian R Gunther, Ethan B Ludmir
  Advances in Radiation Oncology. 2024-12-01
• Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy.
  Rishika Prasad, Abdur Rehman, Lubna Rehman, Faezeh Darbaniyan, Viktoria Blumenberg
  Blood. 2024-10-23

Journal Articles

• Assessment of Radiation Doses Delivered to Organs at Risk Among Patients with Early-Stage Favorable Hodgkin Lymphoma Treated with Contemporary Radiation Therapy  
  Chelsea C Pinnix, Jillian R Gunther, Sarah A Milgrom, Jason Westin, Simrit Parmar, Loretta Nastoupil, Sattva Neelapu, Bouthaina S Dabaja, JAMA Network Open

Abstracts/Posters

• A Multi-Center Dose-Finding Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Fimepinostat (CUDC-907) in Combination with Venetoclax i...
  Jason R. Westin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Preliminary Clinical Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Subjects with Relapsed or Refractory CD20+ non-Hodgkin Lymphoma
  Jason R. Westin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Analysis of Factors Predictive of Risk of Transformation and Time to Transformation in Patients (pts) with Mantle Cell Lymphoma _ Cohort Study of 369 Patients
  Jason R. Westin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Predictive Factors of Response and Survival of Lenalidomide and Rituximab As Initial Treatment of Follicular Lymphoma
  Jason R. Westin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Short Diagnosis-to-Treatment Interval Is Associated with Higher Levels of Circulating Tumor DNA in Aggressive B-Cell Non-Hodgkin Lymphoma
  Jason R. Westin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patie...
  Jason R. Westin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Phase I/II Study to Examine the Safety and Efficacy of Pembrolizumab 200 Mg Fixed Dose Administered Every 3 Weeks (Q3W) in Combination with Romidepsin in Relapsed or...
  Jason R. Westin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Results of a First in Human, Dose Ascending, Phase I Study Examining the Safety and Tolerability of KA2237, an Oral PI3K p110_/_ Inhibitor in Patients with Relapsed/Re...
  Jason R. Westin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Correlation of Bridging and Lymphodepleting Chemotherapy with Clinical Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagen...
  Jason R. Westin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Impact of Tisagenlecleucel Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Attributes on Clinical Outcomes in Adults with Relapsed or Refractory Diffuse Large B...
  Jason R. Westin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Clinical and Radiological Correlates of Neurotoxicity after Standard of Care Axicabtagene Ciloleucel in Patients with Relapsed/Refractory Large B-Cell Lymphoma
  Jason R. Westin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Results of a Phase II Study of Obinutuzumab in Combination with Lenalidomide in Previously Untreated, High Tumor Burden Follicular Lymphoma (FL)
  Jason R. Westin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Comparative Review of 30 Day Non-Relapse Mortality (NRM) in B-Cell Lymphomas Associated with Anti-CD19 Chimeric Antigen Receptor T-Cells (CAR-T) from FDA Database, Cli...
  Jason R. Westin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Phase II Trial of Nivolumab and Ibrutinib for Patients with Relapsed or Refractory Central Nervous System Lymphoma
  Jason R. Westin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Non-Bcl2 Mutations Are Predominant in Patients (pts) with Venetoclax Resistant Mantle Cell Lymphoma (MCL) _ Response and Clinical Outcomes in Ultra-Refractory MCL
  Jason R. Westin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age _ 65 years) with Mantle C...
  Jason R. Westin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age _ 65 years) with Mantle C...
  Jason R. Westin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Radiation Therapy Can be an Effective Bridging Strategy Prior to Axicabtagene Ciloleucel Therapy for Relapsed/Refractory Large B-Cell LymphomaRadiation Therapy Can be ...
  Jason R. Westin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Pat... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Smart start: Final results of rituximab, lenalidomide, and ibrutinib lead in prior to combination with chemotherapy for patients with newly diagnosed diffuse large B-c... 
  2019 ASCO Annual Meeting - 6/1/2019
• Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World ExperienceClinically Re... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Safety of Axicabtagene Ciloleucel CD19 CAR T-Cell Therapy in Elderly Patients with Relapsed or Refractory Large B-Cell Lymphoma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all